Latest Medicago Inc. (MDCGF) Headlines MediMa
Post# of 1
Posted On: 03/10/2014 1:01:44 PM
Latest Medicago Inc. (MDCGF) Headlines
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
Agaia Inc. Appoints Mike Linn as CEO
PR Newswire - Tue Jan 28, 7:00AM CST
Industry Veteran Brings Track Record of Business Development Success to Lead the Rapidly Expanding Company Through Transformative Growth
EFSA's Re-Evaluation Confirms That Health Concern for BPA is Low, says American Chemistry Council
PR Newswire - Fri Jan 17, 8:45AM CST
The American Chemistry Council (ACC) offers the following comments regarding the release of the European Food Safety Authority's (EFSA) "Draft Scientific Opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs." Quotes from the following may be attributed to Steven G. Hentges, Ph.D. of ACC's Polycarbonate/BPA Global Group.
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program
Business Wire - Thu Jan 09, 10:59AM CST
Regulatory News :
360PR Named Public Relations Agency Of Record By Blue Chair Bay Rum
PR Newswire - Tue Jan 07, 9:05AM CST
360PR has been selected as public relations agency of record by Blue Chair Bay, the fast-growing rum brand poised to become one of the most successful spirits launches by an independent company, measured by year one case volume. Created and wholly owned by award winning singer-songwriter Kenny Chesney, Blue Chair Bay was literally born on the beach, where every drop is created and white oak cask-aged at the Caribbean's last true beachside distillery.
General Dynamics CorpCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:53PM CST
Medicago Inc. (TSX: MDG; OCTQX: MDCGF), a biopharmaceutical company specializing in the development of highly effective and competitive vaccines using proprietary manufacturing technologies and virus-like particles (VLPs), and Folia Biotech, a private biotechnology firm that focuses on vaccine enhancement using plant virus recombinant protein (papaya mosaic virus) as an adjuvant, announce the receipt of $415,000 in financial support from the Quebec government and the municipality of Quebec City to fund a feasibility study for a unique biopharmaceutical production project, known as BioProduction21, part of the Quebec Region's Life Science ACCORD Cluster.
Mopar Provides Plenty of Last-Minute Holiday Gift Ideas
PR Newswire - Thu Dec 19, 8:34AM CST
-- Hundreds of Mopar accessories and merchandise available for less than $50 at Mopar.com and Wearmopar.com
Market Research: Rabies - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg2s9p/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H2 2013" report to their offering. 'Rabies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Scope - A snapshot of the global therapeutic scenario for Rabies. - A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rabies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rabies. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Celltrion, Inc. KAKETSUKEN Novavax, Inc. Zydus Cadila Healthcare Limited Crucell N.V. Medicago Inc. NanoViricides, Inc. Kamada Ltd. Isconova AB. Sinovac Biotech Ltd. Serum Institute of India Limited Trellis Bioscience, Inc. Molecular Targeting Technologies, Inc. Prosetta Corporation Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/jg...s_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Philip Morris International Inc. Update on Holding of Medicago Inc.
Business Wire - Wed Sep 18, 8:30AM CDT
Philip Morris International Inc. (NYSE / Euronext Paris: PM) announced today that Philip Morris Investments B.V. (PM Investments), an affiliate of PMI, as part of the previously announced arrangement of Medicago Inc. (Medicago), made on July 12, 2013, acquired 11,348,266 common shares of Medicago for a consideration of CAD $13,163,989.
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago
PR Newswire - Wed Sep 18, 6:50AM CDT
Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC") and Medicago Inc. (TSX:MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC.
Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma
PR Newswire - Thu Sep 12, 6:00AM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement") involving the Company, Mitsubishi Tanabe Pharma Corporation ("MTPC") and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC (the "Purchaser").
Influenza A Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l7tr35/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H2 2013" report to their offering. 'Influenza A Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza A Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza A Infections. Scope - A snapshot of the global therapeutic scenario for Influenza A Infections. - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Influenza A Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Johnson & Johnson Sanofi-Aventis GlaxoSmithKline plc Inovio Biomedical Corporation Daiichi Sankyo Company, Ltd Emergent BioSolutions Inc. Generex Biotechnology Corporation Takeda Pharmaceutical Company Limited Celltrion, Inc. Nanotherapeutics, Inc. Novartis AG Vertex Pharmaceuticals Incorporated CEL-SCI Corporation AVI BioPharma Inc. Crucell N.V. OPKO Health, Inc. Hemispherx Biopharma, Inc. Medicago Inc. NanoViricides, Inc. NovaBay Pharmaceuticals, Inc. Medigen Biotechnology Corp. CytoGenix, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l7...nfluenza_a About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Stockboard Custom Reports on Resverlogix Corp. and Medicago Inc.
ACCESSWIRE - Tue Sep 03, 12:04PM CDT
Custom stock reports and email news alert service for Resverlogix Corp. (TSX:RVX) and Medicago Inc. (TSX: MDG) (OTCQX: MDCGF) are now available on Stockboard.com
Ebola Viral Infections - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g94m3t/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola Viral Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola Viral Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola Viral Infections. Scope - A snapshot of the global therapeutic scenario for Ebola Viral Infections. - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola Viral Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Tekmira Pharmaceuticals Corp. Medicago Inc. CombinatoRx, Incorporated Summit Corporation plc Functional Genetics, Inc. Evolva SA Vaxart, Inc. Prosetta Corporation For more information visit http://www.researchandmarkets.com/research/g9...bola_viral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicago Shareholders Approve Arrangement with Mitsubishi Tanabe Pharma Corporation
CNW Group - Thu Aug 29, 1:33PM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), during today's special meeting of shareholders of Medicago (the"Meeting"), is pleased to annouce that its shareholders have approved the resolution authorizing the previously announced plan of arrangement (the"Arrangement") involving the Company, Mitsubishi Tanabe Pharma Corporation (the"MTPC") and 9284-9686 Québec Inc. (the"Purchaser"), a wholly-owned subsidiary of MTPC.
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
Agaia Inc. Appoints Mike Linn as CEO
PR Newswire - Tue Jan 28, 7:00AM CST
Industry Veteran Brings Track Record of Business Development Success to Lead the Rapidly Expanding Company Through Transformative Growth
EFSA's Re-Evaluation Confirms That Health Concern for BPA is Low, says American Chemistry Council
PR Newswire - Fri Jan 17, 8:45AM CST
The American Chemistry Council (ACC) offers the following comments regarding the release of the European Food Safety Authority's (EFSA) "Draft Scientific Opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs." Quotes from the following may be attributed to Steven G. Hentges, Ph.D. of ACC's Polycarbonate/BPA Global Group.
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program
Business Wire - Thu Jan 09, 10:59AM CST
Regulatory News :
360PR Named Public Relations Agency Of Record By Blue Chair Bay Rum
PR Newswire - Tue Jan 07, 9:05AM CST
360PR has been selected as public relations agency of record by Blue Chair Bay, the fast-growing rum brand poised to become one of the most successful spirits launches by an independent company, measured by year one case volume. Created and wholly owned by award winning singer-songwriter Kenny Chesney, Blue Chair Bay was literally born on the beach, where every drop is created and white oak cask-aged at the Caribbean's last true beachside distillery.
General Dynamics CorpCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:53PM CST
Medicago Inc. (TSX: MDG; OCTQX: MDCGF), a biopharmaceutical company specializing in the development of highly effective and competitive vaccines using proprietary manufacturing technologies and virus-like particles (VLPs), and Folia Biotech, a private biotechnology firm that focuses on vaccine enhancement using plant virus recombinant protein (papaya mosaic virus) as an adjuvant, announce the receipt of $415,000 in financial support from the Quebec government and the municipality of Quebec City to fund a feasibility study for a unique biopharmaceutical production project, known as BioProduction21, part of the Quebec Region's Life Science ACCORD Cluster.
Mopar Provides Plenty of Last-Minute Holiday Gift Ideas
PR Newswire - Thu Dec 19, 8:34AM CST
-- Hundreds of Mopar accessories and merchandise available for less than $50 at Mopar.com and Wearmopar.com
Market Research: Rabies - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg2s9p/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H2 2013" report to their offering. 'Rabies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Scope - A snapshot of the global therapeutic scenario for Rabies. - A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rabies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rabies. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Celltrion, Inc. KAKETSUKEN Novavax, Inc. Zydus Cadila Healthcare Limited Crucell N.V. Medicago Inc. NanoViricides, Inc. Kamada Ltd. Isconova AB. Sinovac Biotech Ltd. Serum Institute of India Limited Trellis Bioscience, Inc. Molecular Targeting Technologies, Inc. Prosetta Corporation Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/jg...s_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Philip Morris International Inc. Update on Holding of Medicago Inc.
Business Wire - Wed Sep 18, 8:30AM CDT
Philip Morris International Inc. (NYSE / Euronext Paris: PM) announced today that Philip Morris Investments B.V. (PM Investments), an affiliate of PMI, as part of the previously announced arrangement of Medicago Inc. (Medicago), made on July 12, 2013, acquired 11,348,266 common shares of Medicago for a consideration of CAD $13,163,989.
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago
PR Newswire - Wed Sep 18, 6:50AM CDT
Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC") and Medicago Inc. (TSX:MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC.
Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma
PR Newswire - Thu Sep 12, 6:00AM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement") involving the Company, Mitsubishi Tanabe Pharma Corporation ("MTPC") and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC (the "Purchaser").
Influenza A Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l7tr35/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H2 2013" report to their offering. 'Influenza A Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza A Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza A Infections. Scope - A snapshot of the global therapeutic scenario for Influenza A Infections. - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Influenza A Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Johnson & Johnson Sanofi-Aventis GlaxoSmithKline plc Inovio Biomedical Corporation Daiichi Sankyo Company, Ltd Emergent BioSolutions Inc. Generex Biotechnology Corporation Takeda Pharmaceutical Company Limited Celltrion, Inc. Nanotherapeutics, Inc. Novartis AG Vertex Pharmaceuticals Incorporated CEL-SCI Corporation AVI BioPharma Inc. Crucell N.V. OPKO Health, Inc. Hemispherx Biopharma, Inc. Medicago Inc. NanoViricides, Inc. NovaBay Pharmaceuticals, Inc. Medigen Biotechnology Corp. CytoGenix, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l7...nfluenza_a About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Stockboard Custom Reports on Resverlogix Corp. and Medicago Inc.
ACCESSWIRE - Tue Sep 03, 12:04PM CDT
Custom stock reports and email news alert service for Resverlogix Corp. (TSX:RVX) and Medicago Inc. (TSX: MDG) (OTCQX: MDCGF) are now available on Stockboard.com
Ebola Viral Infections - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g94m3t/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola Viral Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola Viral Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola Viral Infections. Scope - A snapshot of the global therapeutic scenario for Ebola Viral Infections. - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola Viral Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Tekmira Pharmaceuticals Corp. Medicago Inc. CombinatoRx, Incorporated Summit Corporation plc Functional Genetics, Inc. Evolva SA Vaxart, Inc. Prosetta Corporation For more information visit http://www.researchandmarkets.com/research/g9...bola_viral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicago Shareholders Approve Arrangement with Mitsubishi Tanabe Pharma Corporation
CNW Group - Thu Aug 29, 1:33PM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), during today's special meeting of shareholders of Medicago (the"Meeting"), is pleased to annouce that its shareholders have approved the resolution authorizing the previously announced plan of arrangement (the"Arrangement") involving the Company, Mitsubishi Tanabe Pharma Corporation (the"MTPC") and 9284-9686 Québec Inc. (the"Purchaser"), a wholly-owned subsidiary of MTPC.
(0)
(0)Medicago Inc. (MDCGF) Stock Research Links
Scroll down for more posts ▼